InterStim Therapy -- Sacral Nerve Stimulation (SNS) for Urinary Control
Description:InterStim Therapy for Urinary Control offers a revolutionary approach to managing urinary retention and the symptoms of overactive bladder, including urinary urge incontinence and significant symptoms of urgency-frequency alone or in combination in patients who have failed or could not tolerate more conservative treatments. Medtronic developed InterStim Therapy using more than 13 years of exper...
Company:Medtronic Urology/Urogynecology
Sunesis Pharmaceuticals Reports Positive Data From Studies of Two
Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of
the European Hematology Association
Interim Data from Phase 1 Clinical Trial of
SNS-595 in AcuteLeukemia Demonstrates Additional Clinical Activity SOUTH SAN FRANCISCO, Calif., June 11, 2007/PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. presentedpositive data from clinical studies of two of the company'santi-cancer product candidates,
SNS-595 and
SNS-032, at the 12thCongress of the European Hematology Association (E...
Sunesis Presents Data Supporting SNS-032's Potential Anticancer
Activity in Multiple Myeloma at the American Association for Cancer
Research Meeting
Results from Non-clinical Studies Confirm Mechanism of Action andProvide Guidance for Dosing SOUTH SAN FRANCISCO, April 16, 2007 /PRNewswire-FirstCall/ --Sunesis Pharmaceuticals, Inc. presented non-clinical datademonstrating
SNS-032's apoptotic activity in a multiple myelomamodel. These data were presented today in a poster session duringthe Annual Meeting of the American Association for...
Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor
Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
Research from Non-clinical Studies Presented at the TargetedAnticancer Therapies (TAT 2007) and the Keystone Symposia MolecularTargets for Cancer Meetings Support Phase 1 Trial Design SOUTH SAN FRANCISCO, Calif., March 20, 2007/PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. , presentednon-clinical data on its development-stage compound,
SNS-314, attwo leading scientific meetings f...